Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Schiff

Showing results (271-280 of 305) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2021
Treatment for Brain Metastases: ASCO-SNO-ASTRO GuidelineMichael A Vogelbaum, Paul D Brown, Hans Messersmith, et al.
Neuro-Oncology|November 1, 2021
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adultsDidier Frappaz, Girish Dhall, Matthew J Murray, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupD Ross Camidge, Eudocia Q Lee, Nancy U Lin, et al.
The Lancet. Oncology|December 19, 2015
Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) groupIsabelle Thibault, Eric L Chang, Jason Sheehan, et al.
Journal of Neuro-Oncology|October 23, 2014
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomasAndrew D Norden, David Schiff, Manmeet S Ahluwalia, et al.
Neuro-Oncology|March 29, 2018
Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group reportIlya Laufer, Simon S Lo, Eric L Chang, et al.
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
Neuro-Oncology|July 18, 2020
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study designKurt A Jaeckle, Karla V Ballman, Martin van den Bent, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Discovery and therapeutic exploitation of Master Regulatory miRNAs in GlioblastomaShekhar Saha, Ying Zhang, Myron Keith Gibert, et al.
The New England Journal of Medicine|February 21, 2014
A randomized trial of bevacizumab for newly diagnosed glioblastomaMark R Gilbert, James J Dignam, Terri S Armstrong, et al.
Pageof 31

Showing results (271-280 of 305) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2021
Treatment for Brain Metastases: ASCO-SNO-ASTRO GuidelineMichael A Vogelbaum, Paul D Brown, Hans Messersmith, et al.
Neuro-Oncology|November 1, 2021
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adultsDidier Frappaz, Girish Dhall, Matthew J Murray, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupD Ross Camidge, Eudocia Q Lee, Nancy U Lin, et al.
The Lancet. Oncology|December 19, 2015
Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) groupIsabelle Thibault, Eric L Chang, Jason Sheehan, et al.
Journal of Neuro-Oncology|October 23, 2014
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomasAndrew D Norden, David Schiff, Manmeet S Ahluwalia, et al.
Neuro-Oncology|March 29, 2018
Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group reportIlya Laufer, Simon S Lo, Eric L Chang, et al.
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
Neuro-Oncology|July 18, 2020
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study designKurt A Jaeckle, Karla V Ballman, Martin van den Bent, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Discovery and therapeutic exploitation of Master Regulatory miRNAs in GlioblastomaShekhar Saha, Ying Zhang, Myron Keith Gibert, et al.
The New England Journal of Medicine|February 21, 2014
A randomized trial of bevacizumab for newly diagnosed glioblastomaMark R Gilbert, James J Dignam, Terri S Armstrong, et al.
Pageof 31